Patient dosimetry in nuclear medicine

EFFECTIVE DOSE TO ADULT PATIENTS UNDERGOING RENAL SCANS WITH 99MTC (DMSA, DTPA, EC AND MAG3)

Renal scintigraphy plays an important role in the diagnosis of various kidney disorders. This procedure can be performed with different radiopharmaceuticals. The patients undergoing renal scintigraphy receive a radiation dose that should be assessed. In this study, the effective dose of patients due to renal scintigraphy with 99mTc (DMSA, DTPA, EC and MAG3) was calculated for the International Commission on Radiological Protection (ICRP) 110 adult reference phantoms using the Medical Internal Radiation Dose method and the ICRP 60 and 103 tissue weighting factors. The results show that the highest effective dose per unit activity administered is due to 99mTc DMSA. On average, the effective dose per unit activity administered of 99mTc DMSA is almost twice the effective dose per unit activity administered of other radiopharmaceuticals. The effective doses per unit activity administered calculated using the ICRP 103 tissue weighting factors are always lower than that calculated using the ICRP 60 tissue weighting factors and the ICRP 128 data.

Optimization of newly developed and lead shields thicknesses for protecting taxi drivers from 99mTc injected patients

Presently, public members are exposed to sources of ionizing radiation, and health risks due to radiation exposures should be a concern. This study aims to calculate the whole-body cumulative radiation exposure of taxi drivers. Also, this study will provide the effect of using a simple lead shield and three types of glass shield AVT6, TZN-D, and SLGC-E5, by calculating the effective annual dose of the taxi drivers that work in medical centers. Two MIRD phantoms as a driver and patient, a sample body of a taxi, pure lead, and glass sheets as a shield, were simulated using the MCNP code. We assumed that the patients had undergone the brain, liver, and kidney SPECT imaging by injecting 99mTC-HMPAO, 99mTC-sulfur colloid, and 99mTC-DMSA with the activity of 740MBq, 185MBq, and 333MBq, respectively. These shields are simulated on two sides of the driver, in the back and right side. The annual effective dose was calculated for 0-3.5 g/cm² area densities. It was observed that the 0.45, 1.09, 1.28, and 2.11 g/cm² of Pb, TZN-D, AVT6, and SLGC-E5 respectively decrease the effective dose below the allowed limit. According to the results, using the lead shield, the effective dose was reduced by a factor up to 7.25 times. It is recommended that taxi drivers wear a 0.4 mm lead shield or its equivalent when they have Tc-99 m injected patients.

Development of a 99mTc-Labeled Single-Domain Antibody for SPECT/CT Assessment of HER2 Expression in Breast Cancer

Accurate determination of human epidermal growth factor receptor 2 (HER2) expression is essential for HER2-targeted therapy in patients with cancer. HER2 expression in a complex environment, such as in a heterogeneous tumor, makes the precise assessment of the HER2 status difficult using current methods. In this study, we developed a novel ^99mTc-labeled anti-HER2 single-domain antibody (^99mTc-NM-02) as a molecular imaging tracer for the noninvasive detection of HER2 expression and investigated its safety, radiation dosimetry, biodistribution, and tumor-targeting potential in 10 patients with breast cancer. Our data showed that no drug-related adverse reactions occurred. The tracer mainly accumulated in the kidneys and liver with mild uptake in the spleen, intestines, and thyroid; however, only background tracer levels were observed in other organs where primary tumors and metastases typically occurred. The mean effective dose was 6.56 × 10^-3 mSv/MBq, and tracer uptake was visually observed in the primary tumors and metastases. A maximal standard uptake value of 1.5 was determined as a reasonable cutoff for identifying HER2 positivity using SPECT/CT imaging. Our ^99mTc-NM-02 tracer is safe for use in breast cancer imaging, with reasonable radiation doses, favorable biodistribution, and imaging characteristics. ^99mTc-NM-02 SPECT imaging may be an accurate and noninvasive method to detect the HER2 status in patients with breast cancer.

Population exposure-response model of 131I in patients with benign thyroid disease

PURPOSE

The study aimed to explore the relationship of different exposure measures with ¹³¹I therapy response in patients with benign thyroid disease, estimate the variability in the response, investigate possible covariates, and discuss dosing implications of the results.

METHODS

A population exposure-response analysis was performed using nonlinear mixed-effects modelling. Data from 95 adult patients with benign thyroid disease were analysed. Evaluated exposure parameters were: administered radioactivity dose (Aa) [MBq], total absorbed dose (ABD) [Gy], maximum of absorbed dose-rate (MXR) [Gy/h] and biologically effective dose (BED) [Gy]. The response was modelled as ordered categorical data: hyper-, eu- and hypothyroidism. The final model performance was evaluated by a visual predictive check.

RESULTS

The probability of the outcome following ¹³¹I therapy was best described by a proportional-odds model, including the log-linear model of ¹³¹I effect and the exponential model of the response-time relationship. All exposure measures were statistically significant with p<0.001, with BED and ABD being statistically better than the other two. Nevertheless, as BED resulted in the lowest AIC value, it was included in the final model. Accordingly, BED value of 289.7 Gy is associated with 80% probability of successful treatment outcome 12 months after ¹³¹I application in patients with median thyroid volume (32.28 mL). The target thyroid volume was a statistically significant covariate. The visual predictive check of the final model showed good model performance.

CONCLUSION

Our results imply that BED formalism could aid in therapy individualisation. The larger thyroid volume is associated with a lower probability of a successful outcome.

Managing radioiodine refractory thyroid cancer: the role of dosimetry and redifferentiation on subsequent I-131 therapy

Poor responses to iodine-131 (I-131) therapy can relate to either low iodine uptake and retention in thyroid cancer cells or to increased radioresistance. Both mechanisms are currently termed radioactive iodine (RAI)-refractory (RAI-R) thyroid cancer but the first reflects unsuitability for I-131 therapy that can be evaluated in advance of treatment, whereas the other can only be identified post hoc. Management of both represents a considerable challenge in clinical practice as failure of I-131 therapy, the most effective treatment of metastatic thyroid cancer, is associated with a poor overall prognosis. The development of targeted therapies has shown substantial promise in the treatment of RAI-R thyroid cancer in progressive patients. Recent studies show that selective tyrosine kinase inhibitors (TKIs) targeting B-type rapidly accelerated fibrosarcoma kinase (BRAF) and mitogen-activated protein kinase (MEK) can be used as redifferentiation agents to re-induce RAI uptake, thereby (re)enabling I-131 therapy. The use of dosimetry prior- and post-TKI treatment can assist in quantifying RAI uptake and improve identification of patients that will benefit from I-131 therapy. It also potentially offers the prospect of calculating individualized therapeutic administered activities to enhance efficacy and limit toxicity. In this review, we present an overview of the regulation of RAI uptake and clinically investigated redifferentiation agents, both reimbursed and in experimental setting, that induce renewed RAI uptake. We describe the role of dosimetry in redifferentiation and subsequent I-131 therapy in RAI-R thyroid cancer, explain different dosimetry approaches and discuss limitations and considerations in the field.

Orthorhombic HfO2 with embedded Ge nanoparticles in nonvolatile memories used for the detection of ionizing radiation

Trilayer memory capacitors of control HfO₂/floating gate of Ge nanoparticles in HfO₂/tunnel HfO₂/Si substrate deposited by magnetron sputtering and subsequently annealed are investigated for the first time for applications in radiation dosimetry. In the floating gate (FG), amorphous Ge nanoparticles (NPs) are arranged in two rows inside the HfO₂ matrix. The HfO₂ matrix is formed of orthorhombic/tetragonal nanocrystals (NCs). The adjacent thin films to the FG are also formed of orthorhombic/tetragonal HfO₂ NCs. This phase is formed during annealing, in samples with thick control HfO₂, in the presence of Ge, being induced by the stress. In the rest of the control oxide, HfO₂ NCs are monoclinic. Orthorhombic HfO₂ has ferroelectric properties and therefore enhances the memory window produced by charge storage in Ge NPs to above 6 V. The high sensitivity of 0.8 mV Gy^-1 to α particle irradiation from a ²⁴¹Am source was measured by monitoring the flatband potential during radiation exposure after electrical writing of the memory.

Radionuclide therapy: current status and prospects for internal dosimetry in individualized therapeutic planning

The efficacy and toxicity of radionuclide therapy are believed to be directly related to the radiation doses received by target tissues; however, nuclear medicine therapy continues to be based primarily on the administration of empirical activities to patients and less frequently on the use of internal dosimetry for individual therapeutic planning. This review aimed to critically describe the techniques and clinical evidence of dosimetry as a tool for therapeutic planning and the main limitations to its implementation in clinical practice. The present article is a nonsystematic review of voxel-based dosimetry. Clinical evidence pointing to a correlation between the radiation dose and therapeutic response in various diseases, such as thyroid carcinoma, neuroendocrine tumors and prostate cancer, is reviewed. Its limitations include technical aspects related to image acquisition and processing and the lack of randomized clinical trials demonstrating the impact of dosimetry on patient therapy. A more widespread use of dosimetry in therapeutic planning involves the development of user-friendly dosimetric protocols and confirmation that dose estimation implies good efficacy and low treatment-related toxicity.

Biological Response of Positron Emission Tomography Scan Exposure and Adaptive Response in Humans

The biological effects of exposure to radioactive fluorodeoxyglucose (¹⁸F-FDG) were investigated in the lymphocytes of patients undergoing positron emission tomography (PET) procedures. Low-dose, radiation-induced cellular responses were measured using 3 different end points: (1) apoptosis; (2) chromosome aberrations; and (3) γH2AX foci formation. The results showed no significant change in lymphocyte apoptosis, or chromosome aberrations, as a result of in vivo ¹⁸F-FDG exposure, and there was no evidence the PET scan modified the apoptotic response of lymphocytes to a subsequent 2 Gy in vitro challenge irradiation. However, lymphocytes sampled from patients following a PET scan showed an average of 22.86% fewer chromosome breaks and 39.16% fewer dicentrics after a subsequent 2 Gy in vitro challenge irradiation. The effect of ¹⁸F-FDG exposure on phosphorylation of histone H2AX (γH2AX) in lymphocytes of patients showed a varied response between individuals. The relationship between γH2AX foci formation and increasing activity of ¹⁸F-FDG was not directly proportional to dose. This variation is most likely attributed to differences in the factors that combine to constitute an individual’s radiation response. In summary, the results of this study indicate¹⁸F-FDG PET scans may not be detrimental but can elicit variable responses between individuals and can modify cellular response to subsequent radiation exposures.